These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16800922)

  • 21. Fluorescence analysis of the labile iron pool of mammalian cells.
    Epsztejn S; Kakhlon O; Glickstein H; Breuer W; Cabantchik I
    Anal Biochem; 1997 May; 248(1):31-40. PubMed ID: 9177722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different cytoprotective effect of antioxidants and change in the iron regulatory system in rodent cells exposed to paraquat or formaldehyde.
    Ayaki H; Lee MJ; Sumino K; Nishio H
    Toxicology; 2005 Mar; 208(1):73-9. PubMed ID: 15664434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcein as a fluorescent iron chemosensor for the determination of low molecular weight iron in biological fluids.
    Ali A; Zhang Q; Dai J; Huang X
    Biometals; 2003 Jun; 16(2):285-93. PubMed ID: 12572687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations.
    Sturm B; Goldenberg H; Scheiber-Mojdehkar B
    Eur J Biochem; 2003 Sep; 270(18):3731-8. PubMed ID: 12950256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes.
    Ma Y; de Groot H; Liu Z; Hider RC; Petrat F
    Biochem J; 2006 Apr; 395(1):49-55. PubMed ID: 16336208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Deferoxamine protects against gentamicin ototoxicity].
    Chen Y; Wang J; Huang W
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Jun; 34(3):154-6. PubMed ID: 12764806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis.
    Tenopoulou M; Doulias PT; Barbouti A; Brunk U; Galaris D
    Biochem J; 2005 May; 387(Pt 3):703-10. PubMed ID: 15579135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
    Alta EC; Goswami D; Machini MT; Silvestre DM; Nomura CS; Espósito BP
    Biometals; 2014 Dec; 27(6):1351-60. PubMed ID: 25265871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron chelation down-regulates dopamine transporter expression by decreasing mRNA stability and increasing endocytosis in N2a cells.
    Hegde NV; Jensen GL; Unger EL
    Exp Cell Res; 2011 Feb; 317(4):405-12. PubMed ID: 21147099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte activation, iron uptake and release by human mononuclear leukocytes in the presence of desferrioxamine.
    Taylor PG; Soyano A; Romano E; Layrisse M
    Immunopharmacol Immunotoxicol; 1988; 10(2):165-78. PubMed ID: 3171105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of iron deprivation on multidrug resistance of leukemic K562 cells.
    Fang D; Bao Y; Li X; Liu F; Cai K; Gao J; Liao Q
    Chemotherapy; 2010; 56(1):9-16. PubMed ID: 20185911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model.
    Simonart T; Boelaert JR; Andrei G; van den Oord JJ; Degraef C; Hermans P; Noel JC; Van Vooren JP; Heenen M; De Clercq E; Snoeck R
    Int J Cancer; 2002 Jul; 100(2):140-3. PubMed ID: 12115561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Deferoxamine induces apoptosis of HL-60 cells by activating caspase-3].
    Wang D; Liu YF; Wang YC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):485-7. PubMed ID: 16800926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of fluorescence methods for assessing labile iron in cells and biological fluids.
    Espósito BP; Epsztejn S; Breuer W; Cabantchik ZI
    Anal Biochem; 2002 May; 304(1):1-18. PubMed ID: 11969183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of IRP2 mRNA, TfR mRNA and Fn mRNA in HL-60 cells].
    Liu YF; Zhang CX; Zeng L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):584-8. PubMed ID: 16129039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fl-DFO molecules@mesoporous silica materials: highly sensitive and selective nanosensor for dosing with iron ions.
    Su BL; Moniotte N; Nivarlet N; Chen LH; Fu ZY; Desmet J; Li J
    J Colloid Interface Sci; 2011 Jun; 358(1):136-45. PubMed ID: 21420099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells.
    Messer JG; Cooney PT; Kipp DE
    Bone; 2010 May; 46(5):1408-15. PubMed ID: 20102755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of skin cells to UVA-induced necrotic cell death reflects the intracellular level of labile iron.
    Zhong JL; Yiakouvaki A; Holley P; Tyrrell RM; Pourzand C
    J Invest Dermatol; 2004 Oct; 123(4):771-80. PubMed ID: 15373784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.